Bovine lactoferrin ingestion protects against inflammation via IL-11 induction in the small intestine of mice with hepatitis
Authors:
Open Access
- 28 January 2014
- journal article
- research article
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 111 (10) , 1801-1810
Abstract
Accumulating evidence suggests that orally ingested lactoferrin protects against inflammation. To assess the efficacy of orally administered bovine lactoferrin (bLF) against hepatitis and to identify the underlying mechanism, in the present study, we used four mouse models of hepatitis induced byd-galactosamine (GalN), carbon tetrachloride (CCl4), GalN plus lipopolysaccharide (LPS) and zymosan plus LPS. Intraperitoneal (i.p.) injection of GalN (500 mg/kg body weight) in mice treated with bovine serum albumin (BSA) for 14 d significantly increased serum aspartate aminotransferase (AST) concentrations compared with the untreated mice. However, orally administered bLF reduced AST concentrations compared with BSA treatment. In mice that received a single injection (0·4 ml/kg) and twice-weekly injections (0·08 ml/kg) of CCl4for 24 weeks and pretreated with bLF for 14 d and 24 weeks, respectively, significantly suppressed alanine aminotransferase and AST concentrations were observed compared with the BSA-treated control. Oral administration of bLF for 14 d before i.p. injection of LPS (5 mg/kg) plus GalN (1 g/kg) significantly improved the survival rate. In mice that received intravenous injection of zymosan (25 mg/kg) and LPS (15 μg/kg) at 7 d intervals, bLF reduced the elevation of AST concentrations and enhanced the production of IL-11 and bone morphogenetic protein 2 in the small intestine compared with the BSA-treated control. To evaluate the effects of IL-11, we used IL-11 receptor α-null mice treated with GalN, CCl4and zymosan plus LPS. In this group, the activity of bLF was not significantly different from that of BSA. These data indicate that orally ingested bLF enhances the expression of IL-11 in the small intestine and up-regulates protective activity in mice with hepatitis.Keywords
This publication has 43 references indexed in Scilit:
- Lactoferrin Protects Against Acetaminophen-Induced Liver Injury in MiceHepatology, 2009
- Effect of Orally Administered Bovine Lactoferrin on the Growth of Adenomatous Colorectal Polyps in a Randomized, Placebo-Controlled Clinical TrialCancer Prevention Research, 2009
- Bovine lactoferrin potently inhibits liver mitochondrial 8-OHdG levels and retrieves hepatic OGG1 activities in Long-Evans Cinnamon ratsJournal of Hepatology, 2008
- Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balanceJournal of Clinical Investigation, 2007
- Interleukin-11 Receptor Signaling Is Required for Normal Bone RemodelingJournal of Bone and Mineral Research, 2005
- Bone Morphogenetic ProteinsGrowth Factors, 2004
- Recombinant human interleukin 11 and bacterial infection in patients with haemological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trialThe Lancet, 2003
- Interleukin-11 as a Stimulatory Factor for Bone Formation Prevents Bone Loss with Advancing Age in MiceJournal of Biological Chemistry, 2002
- Lactoferrin Inhibits Hepatitis C Virus Viremia in Patients with Chronic Hepatitis C: A Pilot StudyJapanese Journal of Cancer Research, 1999
- Possible Chemopreventive Effects of Bovine Lactoferrin on Esophagus and Lung Carcinogenesis in the RatJapanese Journal of Cancer Research, 1999